155 related articles for article (PubMed ID: 27858873)
21. Dexrazoxane cardioprotection in advanced breast cancer patients undergoing high-dose epirubicin treatment.
Vici P; Ferraironi A; Di Lauro L; Carpano S; Conti F; Belli F; Paoletti G; Maini CL; Lopez M
Clin Ter; 1998; 149(921):15-20. PubMed ID: 9621483
[TBL] [Abstract][Full Text] [Related]
22. Effect of epirubicin-based chemotherapy and dexrazoxane supplementation on QT dispersion in non-Hodgkin lymphoma patients.
Galetta F; Franzoni F; Cervetti G; Cecconi N; Carpi A; Petrini M; Santoro G
Biomed Pharmacother; 2005 Dec; 59(10):541-4. PubMed ID: 16325366
[TBL] [Abstract][Full Text] [Related]
23. Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial.
Fumoleau P; Kerbrat P; Romestaing P; Fargeot P; Brémond A; Namer M; Schraub S; Goudier MJ; Mihura J; Monnier A; Clavère P; Serin D; Seffert P; Pourny C; Facchini T; Jacquin JP; Sztermer JF; Datchary J; Ramos R; Luporsi E
J Clin Oncol; 2003 Jan; 21(2):298-305. PubMed ID: 12525522
[TBL] [Abstract][Full Text] [Related]
24. Neonatal murine engineered cardiac tissue toxicology model: Impact of dexrazoxane on doxorubicin induced injury.
Zhen J; Yu H; Ji H; Cai L; Leng J; Keller BB
Life Sci; 2019 Dec; 239():117070. PubMed ID: 31751580
[TBL] [Abstract][Full Text] [Related]
25. Doxorubicin treatments induce significant changes on the cardiac autonomic nervous system in childhood acute lymphoblastic leukemia long-term survivors.
Caru M; Corbin D; Périé D; Lemay V; Delfrate J; Drouin S; Bertout L; Krajinovic M; Laverdière C; Andelfinger G; Sinnett D; Curnier D
Clin Res Cardiol; 2019 Sep; 108(9):1000-1008. PubMed ID: 30778669
[TBL] [Abstract][Full Text] [Related]
26. Complete recovery of a wide local reaction by the use of dexrazoxane 72 hours after epirubicin extravasation: case report and review of the literature.
Aigner B; Bauernhofer T; Petru E; Niederkorn A; Arzberger EJ; Richtig E
Dermatology; 2014; 229(4):288-92. PubMed ID: 25472626
[TBL] [Abstract][Full Text] [Related]
27. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
Ryberg M; Nielsen D; Cortese G; Nielsen G; Skovsgaard T; Andersen PK
J Natl Cancer Inst; 2008 Aug; 100(15):1058-67. PubMed ID: 18664656
[TBL] [Abstract][Full Text] [Related]
28. Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy.
Wiseman LR; Spencer CM
Drugs; 1998 Sep; 56(3):385-403. PubMed ID: 9777314
[TBL] [Abstract][Full Text] [Related]
29. Tissue-Doppler assessment of cardiac left ventricular function during short-term adjuvant epirubicin therapy for breast cancer.
Appel JM; Sogaard P; Mortensen CE; Skagen K; Nielsen DL
J Am Soc Echocardiogr; 2011 Feb; 24(2):200-6. PubMed ID: 21227647
[TBL] [Abstract][Full Text] [Related]
30. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease.
Tebbi CK; London WB; Friedman D; Villaluna D; De Alarcon PA; Constine LS; Mendenhall NP; Sposto R; Chauvenet A; Schwartz CL
J Clin Oncol; 2007 Feb; 25(5):493-500. PubMed ID: 17290056
[TBL] [Abstract][Full Text] [Related]
31. Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results.
Fumoleau P; Roché H; Kerbrat P; Bonneterre J; Romestaing P; Fargeot P; Namer M; Monnier A; Montcuquet P; Goudier MJ; Luporsi E;
Ann Oncol; 2006 Jan; 17(1):85-92. PubMed ID: 16251204
[TBL] [Abstract][Full Text] [Related]
32. Multicenter study of primary systemic therapy with docetaxel, cyclophosphamide and trastuzumab for HER2-positive operable breast cancer: the JBCRG-10 study.
Ueno T; Masuda N; Sato N; Ohtani S; Yamamura J; Matsunami N; Kashiwaba M; Takano T; Takahashi M; Kaneko K; Ohno S; Morita S; Toi M
Jpn J Clin Oncol; 2020 Jan; 50(1):3-11. PubMed ID: 31821506
[TBL] [Abstract][Full Text] [Related]
33. Long-term effect of epirubicin on incidence of heart failure in women with breast cancer: insight from a randomized clinical trial.
Banke A; Fosbøl EL; Møller JE; Gislason GH; Andersen M; Bernsdorf M; Jensen MB; Schou M; Ejlertsen B
Eur J Heart Fail; 2018 Oct; 20(10):1447-1453. PubMed ID: 29493047
[TBL] [Abstract][Full Text] [Related]
34. Long-term heart function after adjuvant epirubicin chemotherapy for breast cancer.
Appel JM; Zerahn B; Møller S; Christensen HM; Søgaard P; Ejlertsen B; Fogh-Andersen N; Jensen BV; Nielsen DL
Acta Oncol; 2012 Nov; 51(8):1054-61. PubMed ID: 22909389
[TBL] [Abstract][Full Text] [Related]
35. Comparison of mitozantrone and epirubicin in advanced breast cancer.
Cook AM; Chambers EJ; Rees GJ
Clin Oncol (R Coll Radiol); 1996; 8(6):363-6. PubMed ID: 8973851
[TBL] [Abstract][Full Text] [Related]
36. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants.
Hensley ML; Schuchter LM; Lindley C; Meropol NJ; Cohen GI; Broder G; Gradishar WJ; Green DM; Langdon RJ; Mitchell RB; Negrin R; Szatrowski TP; Thigpen JT; Von Hoff D; Wasserman TH; Winer EP; Pfister DG
J Clin Oncol; 1999 Oct; 17(10):3333-55. PubMed ID: 10506637
[TBL] [Abstract][Full Text] [Related]
37. The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin- and mitoxantrone-induced cardiotoxicity.
Herman EH; Zhang J; Rifai N; Lipshultz SE; Hasinoff BB; Chadwick DP; Knapton A; Chai J; Ferrans VJ
Cancer Chemother Pharmacol; 2001 Oct; 48(4):297-304. PubMed ID: 11710630
[TBL] [Abstract][Full Text] [Related]
38. The relationship between post-operative time and cardiac autonomic modulation in breast cancer survivors.
Palma MR; Vanderlei LC; Ribeiro FE; Mantovani AM; Christofaro DG; Fregonesi CE
Int J Cardiol; 2016 Dec; 224():360-365. PubMed ID: 27673692
[TBL] [Abstract][Full Text] [Related]
39. [Preventive effect of low-dose carvedilol combined with candesartan on the cardiotoxicity of anthracycline drugs in the adjuvant chemotherapy of breast cancer].
Liu L; Liu ZZ; Liu YY; Zheng ZD; Liang XF; Han YL; Xie XD
Zhonghua Zhong Liu Za Zhi; 2013 Dec; 35(12):936-40. PubMed ID: 24506965
[TBL] [Abstract][Full Text] [Related]
40. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG).
Polyzos A; Malamos N; Boukovinas I; Adamou A; Ziras N; Kalbakis K; Kakolyris S; Syrigos K; Papakotoulas P; Kouroussis C; Karvounis N; Vamvakas L; Christophyllakis C; Athanasiadis A; Varthalitis I; Georgoulias V; Mavroudis D
Breast Cancer Res Treat; 2010 Jan; 119(1):95-104. PubMed ID: 19636702
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]